UCB SA, a global biopharmaceutical company based in Belgium, focuses on developing innovative medicines and solutions for severe diseases of the immune system or the central nervous system.1
As of August 2025, UCB SA's share price on the Euronext Brussels exchange was €186.85, reflecting a 0.78% increase from the prior week, with a market capitalization of €35,500.79 million.1 On the German exchange (DB), the share price was €195.55 as of August 15, 2025, an increase of 6.08% from the previous week, with a market cap of €35,947.28 million.2
Analyst sentiment for UCB SA remains largely positive, with several firms maintaining "Buy" or "Outperform" ratings throughout 2025. For instance, TD Cowen, Berenberg, Day By Day, ING FM, and HSBC have all maintained "Buy" ratings in various reports through July 2025.1 The average one-year price target for UCB SA is €219.24, with forecasts ranging from a low of €148.47 to a high of €267.75.1
While specific recent press releases directly from UCB SA's official channels were not readily available in the search results, Fintel's platform provides comprehensive financial analysis tools, including institutional ownership data, insider trading records, and options flow, which can offer further insights into UCB SA's market activity and sentiment. Investors can explore UCB SA's detailed financial metrics, such as revenue, operating income, and net income, which are updated regularly on the Fintel platform.3
